| DC Field | Value | Language |
|---|
| dc.contributor.author | Kalitin, K. V. | - |
| dc.contributor.author | Mukha, O. Y. | - |
| dc.contributor.author | Voynov, V. B. | - |
| dc.contributor.author | Spasov, A. A. | - |
| dc.date.accessioned | 2025-11-17T08:53:55Z | - |
| dc.date.available | 2025-11-17T08:53:55Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | The prefrontal cortex as a target for the atypical antipsychotic RU-31 with 5-HT2A antagonistic activity in the treatment of cognitive symptoms / K.V. Kalitin, O.Y. Mukha, V.B. Voynov, A.A. Spasov // Research Results in Pharmacology. - 2025. - Vol.11, №3.-P. 98-108. - Doi: 10.18413/rrpharmacology.11.537. - Refer.: p. 106-108. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/65887 | - |
| dc.description.abstract | This study establishes RU-31 as a promising therapeutic agent for the cognitive symptoms of schizophrenia, demonstrating that it reverses deficits in sensorimotor gating and normalizes PFC neuronal activity through selective 5-HT2A antagonism | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | atypical antipsychotics | ru |
| dc.subject | benzimidazoles | ru |
| dc.subject | molecular docking | ru |
| dc.subject | prepulse inhibition | ru |
| dc.subject | prefrontal cortex | ru |
| dc.subject | schizophrenia | ru |
| dc.subject | cognitive deficits | ru |
| dc.title | The prefrontal cortex as a target for the atypical antipsychotic RU-31 with 5-HT2A antagonistic activity in the treatment of cognitive symptoms | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 11, № 3
|
